Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
August 09, 2023 01:15 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR The Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across...
Global Pet Insurance Market Foreseen to Garner $28,377.8 Million, Growing at 15.3% CAGR in the 2021–2028 Timeframe [235-Pages] | Announced by Research Dive
April 20, 2023 10:25 ET
|
Research Dive
New York, USA, April 20, 2023 (GLOBE NEWSWIRE) -- Research Dive has published a new report on the global pet insurance market. According to the report, the global market is projected to surpass...
With Expanded Outdoor Features, Lifestyle Healing Institute Integrates Traditional and Holistic Medicine
August 29, 2022 08:04 ET
|
Lifestyle Healing Institute
NAPLES, Fla., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Lifestyle Healing Institute, a center for complementary and alternative medicine, treats illnesses with data-driven approaches delivered by a medical...
Growth: Significant Rise in the Adoption of Pets Across the Globe to Propel the Growth of the Global Pet Insurance Market [235-Pages] | Reveals by Research Dive
March 21, 2022 09:05 ET
|
Research Dive
New York, USA, March 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global pet insurance market is expected to generate a revenue of $28,377.8 million by 2028,...
The ASA and the NCCAOM Support the Acupuncture for Our Seniors Act
July 30, 2021 15:22 ET
|
National Certification Commission for Acupuncture and Oriental Medicine
WASHINGTON, July 30, 2021 (GLOBE NEWSWIRE) -- The American Society of Acupuncturists (ASA) and the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) are pleased to...
Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021
June 02, 2021 01:15 ET
|
Novartis Pharma AG
Phase III JUNIPERA study met its primary endpoint, with Cosentyx® (secukinumab) showing significantly longer time to flare (longer time to worsening of symptoms1) vs. placebo (P<.001) in pediatric...
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
June 01, 2021 16:30 ET
|
Novartis Pharma AG
Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo1 The...
“Return to Life” Documentary Reveals Neuro-Acupuncture Success
May 28, 2021 14:14 ET
|
National Certification Commission for Acupuncture and Oriental Medicine
SANTA FE, N.M., May 28, 2021 (GLOBE NEWSWIRE) -- New documentary “Return to Life” premiered internationally via Zoom on Friday, May 7, 2021. From award-winning director Doug Dearth (“9000 Needles”),...
Traditional Naturopath Shares Inspiring Journey to Healing from Addiction, Chronic Illness in Debut Memoir
January 19, 2021 07:00 ET
|
Balboa Press
GIBSON, La., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Author and traditional naturopath Michelle L. Potter has published her uplifting memoir that invites readers to share in Potter’s persistence and...
Seven Leading Non-Profit Providers Leverage Experience Treating Patients with Advanced Illness at Home for New, Unique Medicare Care Model
December 08, 2020 19:12 ET
|
Capital Caring
Falls Church, Virginia, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Seven of the nation’s largest and well-known non-profit advanced illness providers have formed Advanced Illness Partners (AIP) to...